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OBJECTIVE: To determine age-related variations in prostate
cancer (PC) patients’ utilities. PC is a disease of older men. Deci-
sions regarding its management are sensitive to preferences for
outcomes. METHODS: We derived a population-based sample
of PC patients diagnosed in 1992, 1997 or 2002 from the
Ontario Cancer Registry. Patients (n = 1531). Consenting sur-
vivors were mailed questionnaires, includingdemographics,
Health Utilities Index (HUI2/3), and UCLA Prostate Cancer
Index (PCI). We computed Pearson’s correlations between HUI3
utility and PCI scores in all patients and between age quartiles.
We used regression to test for interactions, namely linear trends
in HUI3-PCI slopes across age quartiles. RESULTS: The ﬁrst 289
patients returned questionnaires in 2004. Mean age was 71.6
years. Primary treatments, received 1–11 years prior, were
prostatectomy (46%), radiation (32%), hormones only (12%),
and watchful waiting (10%). Mean HUI3 utility was 0.79, SD
= 0.24. HUI3 and sexual function scores decreased with age (p
< 0.001), but urinary function improved (p = 0.01), with no
changes in bother scores. For HUI3 and sexual function, r = 0.43
(p < 0.001) for 44–65yr olds, and r = 0.14 (p = 0.28.) for 78–
92yr olds, p = 0.35 for interaction. For HUI3 and sexual bother,
r = 0.41 for 44–65yr olds, and r = 0.09 for 78–92yr olds, p =
0.06 for interaction. Correlations between HUI3 and urinary
function increased with age (from 0.24 to 0.43, p = 0.04 for
interaction). Similar age effects were observed for urinary bother.
There were no age-related trends for correlations between HUI3
and bowel function or bother. Sexual and urinary function scores
became less strongly related to their corresponding bother scores
as age increased (p < 0.002). CONCLUSIONS: Although sexual
dysfunction increased with age, it became less bothersome and
had less impact on utility. However, older patients’ quality of life
was more affected by urinary dysfunction. Modelers and policy-
makers may need to adjust utilities for PC health states for
patient age.
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OBJECTIVES: To determine whether lung cancer patients can
be engaged to report their own toxicity-related symptoms during
chemotherapy. METHODS: The NCI’s Common Terminology
Criteria for Adverse Events (CTCAE) schema for nine common
symptoms was adapted into a web-based patient-reporting
system, accessible from computers in outpatient clinics and from
home computers. Outpatients with lung malignancies beginning
standard chemotherapy regimens were invited to enroll. During
a 16-week observation period, participants were encouraged to
login and report symptoms at each follow-up visit, or alterna-
tively to access the system from home. Severe toxicities entered
into the system (grade 3–4) triggered emails to the primary clin-
ical team. RESULTS: A total of 108 patients were approached,
with 23 refusals due to anxiety (n = 4), unwillingness to use a
computer (n = 5), or no perceived beneﬁt (n = 6). All 93 enrollees
completed an initial login. At each subsequent appointment,
most enrollees (80–85%) reported symptoms using the online
system, with a mean of 7 visits per patient (range 1–16). A total
of 79/93 (85%) logged in at more than two-thirds of appoint-
ments. Only 12/93 (13%) voluntarily logged in at least once
from home, with a mean of 10 logins among home users versus
6 among non-home users. Utilization was signiﬁcantly associated
with prior Internet experience but not with age, cancer type,
ECOG score, income, or education level. A total of 121 severe
toxicities were entered into the system, including 17 from home
users, which were delivered via email to treating clinicians for
consideration of interventions. CONCLUSION: Lung cancer
patients are capable of reporting symptoms experienced during
chemotherapy via the web, but may be less willing than other
populations to use computers, and less apt to self-report from
home. Assessment in other populations, in a clinical trial setting,
and comparison of patient versus clinician symptom reporting
are being performed in separate studies.
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OBJECTIVE: Anti-Coagulant therapy is often prescribed for
patients in the hospitals who are at high risk for a deep vein
thrombosis or pulmonary embolism (DVT/PE). The purpose of
this study is to determine if there are better outcomes for patients
who start anti-coagulant therapy on day one as opposed to later
in their stay. METHODS: A retrospective study was conducted
with 391,253 patients who had Lovenox discharged between
January 2001 through June 2005 extracted from Solucient’s
ACTracker Database and grouped into a cohort of 206,456
patients who received the drug on day one and a group of
184,797 patients who received the drug afterwards as the com-
parison group. Economic and clinical outcomes were measured
with the following metrics by different risk adjust methods 1).
length of stay (LOS), ICU LOS, and total costs within risk
adjusted RDRGs, as well as 2). the results of Risk-Adjusted Mor-
tality (RAMI) and Complication (ECRI) indices. RESULTS: In
comparing those patients who received an anti-coagulant on the
ﬁrst day versus anytime after, we found that day one treated
patients had signiﬁcantly shorter weighted average and ICU
weighted average LOS with a difference of 0.87 days (p <
0.0001) and 0.40 days (p < 0.0001) on average respectively. A
signiﬁcantly decreased weighted average total cost in patients
receiving the drug earlier was also observed with a difference of
$806 (p < 0.0001). In clinical perspectives, earlier treated
Lovenox patients were found to have both lower mortality index
(0.96 vs. 1.04, p < 0.0001) and lower complication rates (0.94
vs. 1.05, p < 0.01). CONCLUSION: Patients who received pro-
phylaxis anti-coagulant therapy on their ﬁrst day of an inpatient
stay have better economic and clinical outcomes than those who
receive anti-coagulants later in their stay.
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OBJECTIVES: Mortality and morbidity of patients with Coro-
nary Artery Bypass Grafting (CABG) reoperation (redo) are
reportedly signiﬁcantly higher than those of ﬁrst-time CABG
population. Performing initial CABG properly and preventing
